HC Wainwright & Co. Reiterates Buy on Eledon Pharma, Maintains $13 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino has reiterated a Buy rating on Eledon Pharma (NASDAQ:ELDN) and maintained a price target of $13.
November 13, 2023 | 12:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Vernon Bernardino reaffirmed a Buy rating on Eledon Pharma with a $13 price target, indicating a positive outlook for the stock.
The reiteration of a Buy rating and the maintenance of a $13 price target by a reputable analyst could lead to increased investor confidence in Eledon Pharma. This positive endorsement is likely to have a favorable impact on the stock price in the short term as it suggests the analyst sees potential for the stock to rise to the target price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100